GlassScriptPhysician profile
Ginius Pradhan
NPI 1952652307
$2,715.90
in general payments reported to CMS, 2019-2025
27 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $85.21 · 2021: $272 · 2022: $329 · 2023: $568 · 2024: $548 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630 · Education: $38.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.87 |
| Education | $38.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $359.94 | 2019-2025 | Tavneos, Krystexxa |
| Fresenius USA Marketing, INC. | $262.94 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $189.57 | 2021-2024 | |
| Travere Therapeutics, INC. | $172.29 | 2023-2025 | |
| Vifor Pharma, INC. | $167.50 | 2019-2022 | |
| Abbott Laboratories | $149.89 | 2019 | |
| Alexion Pharmaceuticals, INC. | $141.56 | 2019-2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $126.13 | 2019-2025 | Farxiga |
| Baxter Healthcare | $121.13 | 2022-2023 | Renal - Pd |
| Horizon Therapeutics Plc | $118.94 | 2022-2023 | Krystexxa |
| Akebia Therapeutics INC | $116.00 | 2020-2025 | Vafseo |
| Calliditas Therapeutics US INC. | $108.38 | 2022-2024 | Tarpeyo |
| Glaxosmithkline, LLC. | $106.72 | 2022-2025 | Benlysta, Jesduvroq, Shingrix |
| Otsuka America Pharmaceutical, INC. | $103.92 | 2021-2025 | Jynarque |
| Ardelyx, INC. | $92.57 | 2024-2025 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $78.06 | 2021-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $57.57 | 2024 | Lupkynis |
| Nxstage Medical, INC. | $55.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.89 | 2023 | |
| Ani Pharmaceuticals, INC. | $28.53 | 2023 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $22.90 | 2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.88 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $19.49 | 2025 | Prevymis |
| Nuwellis, INC. | $19.28 | 2019 | |
| Radiometer America, INC | $18.42 | 2025 | |
| Novo Nordisk INC | $14.82 | 2023 | Rybelsus, Ozempic |
| Mallinckrodt Hospital Products INC. | $13.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginius Pradhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.